References
- Suh M, Movva N, Jiang X, et al. Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the national (nationwide) inpatient sample. J Infect Dis. 2022;226(Suppl 2):S154–S163. doi:10.1093/infdis/jiac120.
- Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–546. doi:10.1001/archpedi.1986.02140200053026.
- Arriola CS, Kim L, Langley G, et al. Estimated burden of Community-Onset respiratory syncytial Virus-Associated hospitalizations among children aged <2 years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9(5):587–595. doi:10.1093/jpids/piz087.
- Lively JY, Curns AT, Weinberg GA, et al. Respiratory syncytial Virus-Associated outpatient visits among children younger than 24 months. J Pediatric Infect Dis Soc. 2019;8(3):284–286. doi:10.1093/jpids/piz011.
- Shi N, Palmer L, Chu B-C, et al. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a medicaid claims analysis in early-preterm, late-preterm, and full-term infants. J Med Econ. 2011;14(3):335–340. doi:10.3111/13696998.2011.578188.
- Bowser DM, Rowlands KR, Hariharan D, et al. Cost of respiratory syncytial virus infections in US infants: systematic literature review and analysis. J Infect Dis. 2022;226(Suppl 2):S225–S235. doi:10.1093/infdis/jiac172.
- Leader S, Yang H, DeVincenzo J, et al. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health. 2003;6(2):100–106. doi:10.1046/j.1524-4733.2003.00220.x.
- Karron RA. Respiratory syncytial virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, et al., editors. Philadelphia (PA): Elsevier; 2018. p. 943–949.e4.
- Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555. doi:10.1016/S0140-6736(10)60206-1.
- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi:10.1016/S0140-6736(17)30938-8.
- National Foundation for Infectious Diseases. Call to Action: reducing the Burden of RSV across the Lifespan (January 2022) [Internet]. National Foundation for Infectious Diseases. 2022 https://www.nfid.org/publications/call-to-action-reducing-the-burden-of-rsv-across-the-lifespan/.
- Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus–associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–e348. doi:10.1542/peds.2013-0303.
- Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137(6):865–870. doi:10.1067/mpd.2000.110531.
- Parikh RC, McLaurin KK, Margulis AV, et al. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017;6(4):477–486. doi:10.1007/s40121-017-0167-9.
- Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality—United States. MMWR Morb Mortal Wkly Rep. 2018;67(2):71–76.
- Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States. MMWR Morb Mortal Wkly Rep. 2020;70:2021–2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7029a1.htm
- Zheng Z, Warren JL, Shapiro ED, et al. Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups. Pneumonia. 2022;14(1):6. doi:10.1186/s41479-022-00098-x.
- Glaser EL, Hariharan D, Bowser DM, et al. Impact of respiratory syncytial virus on child, caregiver, and family quality of life in the United States: systematic literature review and analysis. J Infect Dis. 2022;226(Suppl 2):S236–S245. doi:10.1093/infdis/jiac183.
- Simões EAF, Chirikov V, Botteman M, et al. Long-term assessment of healthcare utilization 5 years after respiratory syncytial virus infection in US infants. J Infect Dis. 2020;221:1256–1270.
- Esposito S, Abu Raya B, Baraldi E, et al. RSV prevention in all infants: which is the most preferable strategy? Front Immunol. 2022;13:880368.
- Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008-2013. Ann Am Thorac Soc. 2018;15(3):348–356. doi:10.1513/AnnalsATS.201703-259OC.
- Bont L, Weil Olivier C, Herting E, et al. The assessment of future RSV immunizations: how to protect all infants? Front Pediatr. 2022;10:981741.
- Mac S, Sumner A, Duchesne-Belanger S, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review. Pediatrics. 2019;143:e20184064. doi:10.1542/peds.2018-4064.
- Cohen J. Two new medicines may curb serious respiratory disease in infants. 2020 https://www.science.org/content/article/two-new-medicines-may-curb-serious-respiratory-disease-infants.
- Ananworanich J, Heaton PM. Bringing preventive RSV monoclonal antibodies to infants in low- and Middle-Income countries: challenges and opportunities. Vaccines. 2021;9:961. doi:10.3390/vaccines9090961.
- Institute for Quality and Efficiency in Health Care. The innate and adaptive immune systems. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2020
- Alberts B, Johnson A, Lewis J, et al. The adaptive immune system. In: Molecular biology of the cell. 4th ed. New York: Garland Science; 2002. https://www.ncbi.nlm.nih.gov/books/NBK21070/
- Centers for Disease Control and Prevention. Types of Immunity to a Disease [Internet] 2022. https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm
- Eichinger KM, Kosanovich JL, Lipp M, et al. Strategies for active and passive pediatric RSV immunization. Ther Adv Vaccines Immunother. 2021;9:2515135520981516. doi:10.1177/2515135520981516.
- Li Y, Hodgson D, Wang X, et al. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and Middle-income countries: a modelling study. Lancet Infect Dis. 2021;21(9):1303–1312. doi:10.1016/S1473-3099(20)30703-9.
- Jewett CF, Approves RSV. Shot for Infants. The New York Times [Internet] 2023. https://www.nytimes.com/2023/07/17/health/rsv-infants-fda.html
- Domachowske J, Madhi SA, Simões EAF, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892–894. doi:10.1056/NEJMc2112186.
- Simões EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180–189. doi:10.1016/S2352-4642(22)00321-2.
- Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) Charter [Internet]. 2022 https://www.cdc.gov/vaccines/acip/committee/charter.html
- National Information Center on Health Services Research & Health Care Technology. HTA 101: Introduction to Health Technology Assessment [Internet]. U.S. National Library of Medicine; 2019. https://www.nlm.nih.gov/nichsr/hta101/ta10103.html
- Centers for Disease Control and Prevention. ACIP Evidence to Recommendations Framework. https://www.cdc.gov/vaccines/acip/recs/grade/downloads/acip-evidence-recs-framework.pdf
- Centers for Disease Control and Prevention. Who Sets the Immunization Schedule?. Centers for Disease Control and Prevention. 2021. https://www.cdc.gov/vaccines/parents/schedules/sets-schedule.html
- Bell BP, Romero JR, Lee GM. Scientific and ethical principles underlying recommendations from the advisory committee on immunization practices for COVID-19 vaccination implementation. JAMA. 2020;324(20):2025–2026. doi:10.1001/jama.2020.20847.
- Centers for Disease Control and Prevention. About the Vaccines for Children Program (VFC). [Internet]. 2023. https://www.cdc.gov/vaccines/programs/vfc/about/index.html
- Centers for Disease Control and Prevention. ACIP Resolutions for Vaccines for Children (VFC) Program [Internet]. 2023. https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html
- Centers for Disease Control and Prevention. Immunization Schedules for 18 & Younger [Internet]. Centers for Disease Control and Prevention. 2023. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html
- Smagh K. Advisory committee on immunization practices. Action: notice and request for comment [internet]. Report No.: Docket No. CDC-2023-0063. Centers for Disease Control and Prevention. 2023. https://public-inspection.federalregister.gov/2023-15190.pdf
- Oliver S. Updates to COVID-19 vaccine policy: considerations for Future Planning [Internet]. 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-04-19/06-COVID-Oliver-508.pdf.
- Ku L, Tyler F, Simon M. Vaccines for Children Program: early Legislative History and Future Innovations [Internet]. The George Washington University Milken Institute School of Public Health; 2022. Available from: http://gwhpmmatters.com/sites/default/files/2022-10/VFC_Legislative%20History%20final%2010-13-22%5B9%5D.pdf.
- Neumann PJ, Ganiats TG, Russell LB, et al. editors. Cost-Effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016. https://oxford.universitypressscholarship.com/10.1093/acprof:oso/9780190492939.001.0001/acprof-9780190492939
- Adler MD. Measuring social welfare: an introduction. New York: Oxford University Press; 2019. https://oxford.universitypressscholarship.com/10.1093/oso/9780190643027.001.0001/oso-9780190643027
- Gandon S, Mackinnon MJ, Nee S, et al. Imperfect vaccines and the evolution of pathogen virulence. Nature. 2001;414(6865):751–756. doi:10.1038/414751a.
- Anderson EJ, Carosone-Link P, Yogev R, et al. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699–704. doi:10.1097/INF.0000000000001533.
- Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–1464. doi:10.1056/NEJMoa2216480.
- Lee C, Gong Y, Brok J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332(7537):328–336. doi:10.1136/bmj.38719.435833.7C.
- Rus M, Groselj U. Ethics of vaccination in childhood—a framework based on the four principles of biomedical ethics. Vaccines. 2021;9:113. doi:10.3390/vaccines9020113.
- Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012;345:e8346. doi:10.1136/bmj.e8346.
- Leidner AJ, Chesson HW, Meltzer MI, et al. Guidance for Health Economics Studies Presented to the Advisory Committee on Immunization Practices (ACIP), 2019 Update [Internet]. 2019. https://www.cdc.gov/vaccines/acip/committee/downloads/Economics-Guidance-for-ACIP-2019.pdf
- Hutton DW. Economic Analysis of Nirsevimab in Pediatric Populations [Internet]. University of Michigan; 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/RSV-Pediatric-02-Hutton-508.pdf
- Wise J. RSV: UK to examine whether to offer monoclonal antibody routinely to all babies. BMJ. 2022;379:o2725. doi:10.1136/bmj.o2725.
- Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J. 2012;12(3):228–243.
- Marcotte H, Hammarström L. Chapter 71 - Passive immunization: toward magic bullets. In: Mestecky J, Strober W, Russell MW, et al. editors. Mucosal immunology. 4th edn. Boston: Academic Press; 2015. p. 1403–1434.
- Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy Late-Preterm and term infants. N Engl J Med. 2022;386(9):837–846. doi:10.1056/NEJMoa2110275.
- Young B, Sadarangani S, Jiang L, et al. Duration of influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of Test-Negative design Case-Control studies. J Infect Dis. 2018;217(5):731–741. doi:10.1093/infdis/jix632.
- Centers for Disease Control and Prevention. Learn more about the flu season [Internet]. Centers for Disease Control and Prevention. 2022. https://t.cdc.gov/C03
- Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.
- Zeng Y, Luo M, Lin J, et al. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang province, east China. Hum Vaccin Immunother. 2020;16(4):955–964. doi:10.1080/21645515.2019.1688031.